Luke Pett1, Konstantinos Kiakos1, Vijay Satam2, Pravin Patil2, Sarah Laughlin-Toth3, Matthew Gregory2, Michael Bowerman2, Kevin Olson2, Mia Savagian2, Megan Lee2, Moses Lee4, W David Wilson3, Daniel Hochhauser1, John A Hartley5. 1. Cancer Research UK Drug-DNA Interactions Research Group, UCL Cancer Institute, London, WC1E 6BT, UK. 2. Department of Chemistry, Hope College, Holland, MI 49423, United States. 3. Department of Chemistry, Georgia State University, Atlanta, GA 30303, United States. 4. Department of Chemistry, Hope College, Holland, MI 49423, United States; Department of Chemistry, Georgia State University, Atlanta, GA 30303, United States. 5. Cancer Research UK Drug-DNA Interactions Research Group, UCL Cancer Institute, London, WC1E 6BT, UK. Electronic address: john.hartley@ucl.ac.uk.
Abstract
BACKGROUND: Sequence specific polyamide HxIP 1, targeted to the inverted CCAAT Box 2 (ICB2) on the topoisomerase IIα (topo IIα) promoter can inhibit NF-Y binding, re-induce gene expression and increase sensitivity to etoposide. To enhance biological activity, diamino-containing derivatives (HxI*P 2 and HxIP* 3) were synthesised incorporating an alkyl amino group at the N1-heterocyclic position of the imidazole/pyrrole. METHODS: DNase I footprinting was used to evaluate DNA binding of the diamino Hx-polyamides, and their ability to disrupt the NF-Y:ICB2 interaction assessed using EMSAs. Topo IIα mRNA (RT-PCR) and protein (Immunoblotting) levels were measured following 18h polyamide treatment of confluent A549 cells. γH2AX was used as a marker for etoposide-induced DNA damage after pre-treatment with HxIP* 3 and cell viability was measured using Cell-Titer Glo®. RESULTS: Introduction of the N1-alkyl amino group reduced selectivity for the target sequence 5'-TACGAT-3' on the topo IIα promoter, but increased DNA binding affinity. Confocal microscopy revealed both fluorescent diamino polyamides localised in the nucleus, yet HxI*P 2 was unable to disrupt the NF-Y:ICB2 interaction and showed no effect against the downregulation of topo IIα. In contrast, inhibition of NF-Y binding by HxIP* 3 stimulated dose-dependent (0.1-2μM) re-induction of topo IIα and potentiated cytotoxicity of topo II poisons by enhancing DNA damage. CONCLUSIONS: Polyamide functionalisation at the N1-position offers a design strategy to improve drug-like properties. Dicationic HxIP* 3 increased topo IIα expression and chemosensitivity to topo II-targeting agents. GENERAL SIGNIFICANCE: Pharmacological modulation of topo IIα expression has the potential to enhance cellular sensitivity to clinically-used anticancer therapeutics. This article is part of a Special Issue entitled: Nuclear Factor Y in Development and Disease, edited by Prof. Roberto Mantovani.
BACKGROUND: Sequence specific polyamideHxIP 1, targeted to the inverted CCAAT Box 2 (ICB2) on the topoisomerase IIα (topo IIα) promoter can inhibit NF-Y binding, re-induce gene expression and increase sensitivity to etoposide. To enhance biological activity, diamino-containing derivatives (HxI*P 2 and HxIP* 3) were synthesised incorporating an alkyl amino group at the N1-heterocyclic position of the imidazole/pyrrole. METHODS:DNase I footprinting was used to evaluate DNA binding of the diamino Hx-polyamides, and their ability to disrupt the NF-Y:ICB2 interaction assessed using EMSAs. Topo IIα mRNA (RT-PCR) and protein (Immunoblotting) levels were measured following 18h polyamide treatment of confluent A549 cells. γH2AX was used as a marker for etoposide-induced DNA damage after pre-treatment with HxIP* 3 and cell viability was measured using Cell-Titer Glo®. RESULTS: Introduction of the N1-alkyl amino group reduced selectivity for the target sequence 5'-TACGAT-3' on the topo IIα promoter, but increased DNA binding affinity. Confocal microscopy revealed both fluorescent diamino polyamides localised in the nucleus, yet HxI*P 2 was unable to disrupt the NF-Y:ICB2 interaction and showed no effect against the downregulation of topo IIα. In contrast, inhibition of NF-Y binding by HxIP* 3 stimulated dose-dependent (0.1-2μM) re-induction of topo IIα and potentiated cytotoxicity of topo II poisons by enhancing DNA damage. CONCLUSIONS:Polyamide functionalisation at the N1-position offers a design strategy to improve drug-like properties. Dicationic HxIP* 3 increased topo IIα expression and chemosensitivity to topo II-targeting agents. GENERAL SIGNIFICANCE: Pharmacological modulation of topo IIα expression has the potential to enhance cellular sensitivity to clinically-used anticancer therapeutics. This article is part of a Special Issue entitled: Nuclear Factor Y in Development and Disease, edited by Prof. Roberto Mantovani.
Authors: Sameer Chavda; Yang Liu; Balaji Babu; Ryan Davis; Alan Sielaff; Jennifer Ruprich; Laura Westrate; Christopher Tronrud; Amanda Ferguson; Andrew Franks; Samuel Tzou; Chandler Adkins; Toni Rice; Hilary Mackay; Jerome Kluza; Sharjeel A Tahir; Shicai Lin; Konstantinos Kiakos; Chrystal D Bruce; W David Wilson; John A Hartley; Moses Lee Journal: Biochemistry Date: 2011-03-25 Impact factor: 3.162
Authors: Nicholas G Nickols; Jerzy O Szablowski; Amanda E Hargrove; Benjamin C Li; Jevgenij A Raskatov; Peter B Dervan Journal: Mol Cancer Ther Date: 2013-02-26 Impact factor: 6.261
Authors: Balaji Babu; Yang Liu; Adam Plaunt; Camille Riddering; Ross Ogilvie; Laura Westrate; Ryan Davis; Amanda Ferguson; Hilary Mackay; Toni Rice; Sameer Chavda; David Wilson; Shicai Lin; Konstantinos Kiakos; John A Hartley; Moses Lee Journal: Biochem Biophys Res Commun Date: 2010-12-23 Impact factor: 3.575
Authors: Vijay Satam; Balaji Babu; Alexander Porte; Mia Savagian; Megan Lee; Thomas Smeltzer; Yang Liu; Joseph Ramos; W David Wilson; Shicai Lin; Kostantinos Kiakos; John A Hartley; Moses Lee Journal: Bioorg Med Chem Lett Date: 2012-07-27 Impact factor: 2.823
Authors: Beibei Liu; Luke Pett; Konstantinos Kiakos; Pravin C Patil; Vijay Satam; John A Hartley; Moses Lee; W David Wilson Journal: Chembiochem Date: 2018-08-15 Impact factor: 3.164